Skip to main content

Multiple Sclerosis clinical trials at UCLA

5 in progress, 2 open to eligible people

Showing trials for
  • Metformin Treatment in Progressive Multiple Sclerosis

    open to eligible people ages 30-65

    The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis

    Los Angeles, California

  • Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

    open to eligible people ages 18-50

    This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.

    Torrance, California and other locations

  • Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

    Sorry, in progress, not accepting new patients

    Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 in PPMS and its relationship to efficacy and safety To evaluate pharmacodynamics of SAR442168

    Torrance, California and other locations

  • Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

    Sorry, in progress, not accepting new patients

    A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized 1:1 to either fenebrutinib or teriflunomide. At the end of the DBT phase (after disclosure of the DBT results), the Sponsor will determine whether or not to initiate the open-label extension phase of the study.

    Torrance, California and other locations

  • Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

    Sorry, in progress, not accepting new patients

    FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims: 1) to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and 2) to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.

    Los Angeles, California and other locations

Our lead scientists for Multiple Sclerosis research studies include .

Last updated: